

## **Alberta Drug Benefit List (ADBL) Interim Update now available online**

Please be advised that the July 1, 2015 Updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at <https://www.ab.bluecross.ca/dbl/publications.html>

Please refer to the July 1, 2015 Updates for complete listings of products available by special authorization, step therapy/special authorization, restricted benefit/special authorization, products with changes to criteria for coverage, added products, new interchangeable groupings, least cost alternative price changes, products with a price change, products removed and discontinued products.

Please note that the online *Interactive Drug Benefit List (iDBL)* at [https://www.ab.bluecross.ca/dbl/idbl\\_main1.html](https://www.ab.bluecross.ca/dbl/idbl_main1.html) is a near real time application and, as such, contains the most up to date information.

## **Temporary benefit added to the Alberta Drug Benefit List (ADBL)**

Due to the unavailability of pms-Oxycodone 5 mg Tablet (DIN 02319977), manufactured by Apotex Inc. and Supeudol 5 mg Tablet (DIN 00789739), manufactured by Sandoz Canada Inc., Oxy-IR 5 mg Tablet (DIN 02231934), manufactured by Purdue Pharma, will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of June 22, all claims for Oxy-IR 5 mg Tablet (DIN 02231934) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

## **Removal of temporary benefits from the Alberta Drug Benefit List (ADBL)**

Due to the shortage of Axid 150 mg Capsule (DIN 00778338), manufactured by Pendopharm Inc., Apo-Nizatidine 150 mg Capsule (DIN 02220156), manufactured by Apotex Inc., and Novo-Nizatidine 150 mg Capsule (DIN 02240457), manufactured by Teva Canada Ltd, were added as a temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Pendopharm Inc. has advised Alberta Blue Cross that the shortage of Axid 150 mg Capsule (DIN 00778338) has now been resolved.

As a result, Apo-Nizatidine 150 mg Capsule (DIN 02220156) and Novo-Nizatidine 150 mg Capsule (DIN 02240457) will no longer be considered as temporary benefits for the *ADBL* after **July 24, 2015**.

*Continued on next page ...*

## Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage of pms-Hydroxyzine 2 mg/ml Oral Syrup (DIN 00741817) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping effective **July 24, 2015**.

### HYDROXYZINE HCL

#### 2 MG / ML ORAL SYRUP

00000741817  
00000024694

PMS-HYDROXYZINE  
ATARAX

PMS \$ 0.0476  
ERF \$ 0.0518

---

### When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)  
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)



\*The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.530 2015/06